

Pr *Eliquis*<sup>®</sup>  
apixaban

# #1 DISPENSED NOAC IN CANADA AS PRESCRIBED BY:<sup>1\*</sup>

- ✓ Family Medicine/General Practitioners
- ✓ Cardiologists
- ✓ Neurologists
- ✓ Nephrologists
- ✓ Geriatricians
- ✓ Internal Medicine

ELIQUIS<sup>®</sup> is indicated for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective knee or hip replacement surgery; for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF); for the treatment of venous thromboembolic events (deep vein thrombosis [DVT] and pulmonary embolism [PE]) and for the prevention of recurrent DVT and PE.

Please consult the Product Monograph at [https://www.bms.com/assets/bms/ca/documents/productmonograph/ELIQUIS\\_EN\\_PM.pdf](https://www.bms.com/assets/bms/ca/documents/productmonograph/ELIQUIS_EN_PM.pdf) or <https://www.pfizer.ca/pm/en/eliquis.pdf> for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-866-463-6267.

NOAC = non-vitamin K antagonist oral anticoagulant  
\* Comparative clinical significance unknown.

**References:** 1. IQVIA, Compuscript, January 2020. 2. ELIQUIS Product Monograph. Pfizer Canada ULC and Bristol-Myers Squibb Canada.

Pfizer Canada ULC, Kirkland, Quebec H9J 2M5

Bristol-Myers Squibb Canada Co., Montreal, Quebec H4S 0A4

ELIQUIS and the ELIQUIS wave design are registered trademarks of Bristol-Myers Squibb Company used under license by Bristol-Myers Squibb Canada Co.



**Bristol Myers Squibb**<sup>™</sup>



MEMBER OF  
INNOVATIVE MEDICINES CANADA

